| Exercise Effects in Multiple Sclerosis (NCT05496881) | University of Regina | 2022-06-15 |
| Novel Imaging Markers in SPMS (NCT05357833) | University of Utah | 2022-06-01 |
| Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis (NCT05168384) | Abu Dhabi Stem Cells Center | 2022-03-26 |
| Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis (NCT05122559) | Emmanuelle Waubant, MD PhD | 2022-02-16 |
| MS-ResearchBiomarkerS (NCT05204459) | Cedars-Sinai Medical Center | 2021-11-11 |
| Hydroxychloroquine and Indapamide in SPMS (NCT05013463) | University of Calgary | 2021-10-01 |
| Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). (NCT04260711) | Amsterdam UMC, location VUmc | 2020-07-01 |
| Phase II Clinical Trial of OCH-NCNP1 (NCT04211740) | National Center of Neurology and Psychiatry, Japan | 2019-12-06 |
| Sensitivity of Motor Assessment in MS - a Prospective Cohort Study (NCT04993274) | Friedemann Paul | 2019-02-20 |
| Cortical Lesions in Patients With Multiple Sclerosis (NCT03653585) | Danish Research Centre for Magnetic Resonance | 2018-09-04 |
| Open-label Study of Liothyronine in MS (NCT02506751) | Johns Hopkins University | 2015-07-01 |
| BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis (NCT02430532) | Biogen | 2015-05-01 |
| Domperidone in Secondary Progressive Multiple Sclerosis (SPMS) (NCT02308137) | University of Calgary | 2015-02-01 |
| Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS (NCT02273635) | Innobioscience SpA | 2014-09-01 |
| Imaging of Intracerebral Inflammation in MS (NCT02305264) | Assistance Publique - Hôpitaux de Paris | 2012-03-19 |
| Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis (NCT01433497) | AB Science | 2011-08-01 |
| Bayer/Cognitive Assessments With Multiple Sclerosis Subjects (NCT00888277) | University of Louisville | 2009-05-01 |
| Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis (NCT00587691) | Opexa Therapeutics, Inc. | 2002-07-01 |